Skip to main content
. 2023 Mar 6;15(5):1300. doi: 10.3390/nu15051300

Figure 2.

Figure 2

(A) Changes of plasma levels of IL-6 (mean ± SD) at baseline and at the end of the study in patients treated with DHA supplementation and controls, with significant decreases in the DHA group (p = 0.001) and significant between-group differences (p = 0.001). (B) Changes of VEGF-A (mean ± SD), with a significant decrease in the DHA group (p = 0.011) and with significant between-group differences (p = 0.020).